Why Biocytogen’s RenNano court win could shift the race for fully human VHH antibodies
Discover how Biocytogen’s RenNano court win could reshape VHH antibody licensing, platform risk and next-generation biologics development.
Discover how Biocytogen’s RenNano court win could reshape VHH antibody licensing, platform risk and next-generation biologics development.
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.